In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dusa Pharmaceuticals Inc.

Division of Sun Pharmaceutical Industries Ltd.
www.dusapharma.com

Latest From Dusa Pharmaceuticals Inc.

M&A Trends: The Growing Indian Appetite

A recent round table on pharma industry trends has highlighted the hunger of cash-rich Indian firms for acquiring companies with niche portfolios in regulated markets including the US. Innovator companies shedding their generic units also present significant opportunities for Indian firms. Both trends are expected to build amid apparent Indian interest in the Teva-Allergan divestiture in Europe.

Commercial Deals

Sun Pharma’s $4B Ranbaxy Buy Brings Consumer Products Business With New Growth Focus

In a landmark deal that fits the “made-for-each-other” tag, India’s Sun Pharma agreed to acquire all of Ranbaxy in a $4 billion transaction. While Ranbaxy can hope for a fresh lease on life with tighter regulatory operations under Sun Pharma, analysts said Sun needed to go for a big catch to sustain growth momentum.

BioPharmaceutical Consumer

Sun Pharma’s $4B Ranbaxy Buy Brings Consumer Products Business With New Growth Focus

In a landmark deal that fits the “made-for-each-other” tag, India’s Sun Pharma agreed to acquire all of Ranbaxy in a $4 billion transaction. While Ranbaxy can hope for a fresh lease on life with tighter regulatory operations under Sun Pharma, analysts said Sun needed to go for a big catch to sustain growth momentum.

BioPharmaceutical Consumer

India’s Sun Pharma Buys Ranbaxy As Daiichi Sankyo Exits In A $4 Billion Deal

In a landmark deal that fits the “made-for-each-other” tag, India’s Sun Pharma agreed to acquire all of Ranbaxy in a $4 billion transaction. While Ranbaxy can hope for a fresh lease on life with tighter regulatory operations under Sun Pharma, analysts said Sun needed to go for a big catch to keep its growth momentum.

BioPharmaceutical India
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sun Pharmaceutical Industries Ltd.
  • Senior Management
  • Robert F Doman, Pres. & CEO
    Richard Christopher, VP, Fin. & CFO
    Stuart L Marcus, MD, PhD, SVP, Scientific Affairs & CSO
    William F O'Dell, EVP, Sales & Mktg.
  • Contact Info
  • Dusa Pharmaceuticals Inc.
    Phone: (978) 657-7500
    25 Upton Dr.
    Wilmington, MA 01887
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register